Eteplirsen (Exondys 51) for Duchenne: Price, Availability and Access in Pakistan

Written by the Muscular Dystrophy Pakistan (MDP) content team. Based on regulatory, company and news sources listed below. Prices and availability were checked on October 16, 2026 and can change.

Few medicines have been discussed as much in the Duchenne community as eteplirsen, sold as Exondys 51. Families see it described as the first approved medicine for Duchenne, then see a price of hundreds of thousands of dollars a year, and then ask a painful question: "Can my child get it in Pakistan?" This article gives a clear, honest answer to the questions we hear most: what eteplirsen is, who can use it, what the evidence shows, how much it costs, where it is available, whether it can be brought to Pakistan, how the cost might be reduced, and what the government can do.

Quick facts

• Eteplirsen is a weekly intravenous (IV) infusion for boys whose genetic report shows a change in the DMD gene that is amenable to exon 51 skipping, about 13% to 14% of people with Duchenne.
• The US FDA gave it accelerated approval in 2016, based on a small increase in dystrophin. The label states that a clinical benefit has not been established, and a confirmatory trial is still due to finish in 2026.
• European regulators did not approve it in 2018.
• The cost is weight-based. At current US list prices, it is roughly US$490,000 to US$980,000 per year for children weighing 20 to 40 kg.
• To our knowledge, it is not registered in Pakistan. Unregistered medicines can only be imported with DRAP permission.
• No generic version exists.

New to Duchenne? Start with our complete guide: Duchenne Muscular Dystrophy (DMD): Symptoms, Causes, Life Expectancy and Treatment.

What Is Eteplirsen?

Eteplirsen is an "exon-skipping" medicine. In Duchenne, a genetic change (most often a deletion) disrupts the message for making dystrophin, a protein that protects muscle fibres. Eteplirsen is a short piece of synthetic genetic material that binds to the message and makes the cell skip exon 51. For boys with a matching deletion, this allows a shorter, partly working form of dystrophin to be made, similar to the dystrophin seen in the milder Becker muscular dystrophy.

It is given as an infusion of 30 mg per kilogram of body weight, once a week, over 35 to 60 minutes, into a vein. It has to be given in a hospital or by a trained team, and it has to be continued every week.

Who Can Use Eteplirsen?

Only boys with Duchenne whose confirmed DMD gene change is amenable to exon 51 skipping. This applies to roughly 13% to 14% of people with Duchenne. For everyone else, it does not work, and it should not be used. The first step is therefore a detailed genetic report that gives the exact change in the DMD gene. A CPK test alone, or a muscle biopsy alone, is not enough. Your neurologist or a genetic counsellor can tell you whether your child's change is amenable. Clinical trials of higher doses have mostly enrolled boys who can still walk and are on a stable steroid dose.

What Does the Evidence Show?

This matters, because families should know what they would be paying for.

• FDA accelerated approval (September 2016): The approval was based on a small increase of dystrophin measured in muscle biopsies of a small number of boys, and the FDA said this was "reasonably likely" to predict benefit. The US label states that a clinical benefit, including better movement, has not been established, and that continued approval may depend on a confirmatory trial.
• Confirmatory trial: A trial comparing high doses of eteplirsen (called MIS51ON) is listed with an estimated completion in October 2026, so the full answer is still pending.
• Europe: The European Medicines Agency's committee gave a negative opinion in 2018 and confirmed it after review.
• Cost-effectiveness review: In 2019, the US Institute for Clinical and Economic Review concluded that the evidence was not enough to show a net health benefit over supportive care alone, and said no price could be called a fair value-based price at that point.
• Families' experience: Many families and doctors have reported hope and benefit, which is why the debate continues.

In short: eteplirsen is approved in the US, but its clinical benefit is still being confirmed, and some regulators and cost-effectiveness bodies have not been convinced. This does not mean it is useless, but it means that spending a family's entire savings on it carries real uncertainty.

How Much Does It Cost?

At launch in 2016, the company set the price at around US$300,000 per year for an average patient. The price depends on the child's weight, because the dose is 30 mg/kg every week. In 2026, US pharmacy price guides list about US$1,571 for a 2 mL vial (100 mg) and about US$7,822 for a 10 mL vial (500 mg). Based on these list prices, we estimate the following for 52 weekly doses (excluding hospital, nursing, travel and import costs):

Child's weight	Weekly dose	Estimated cost per year
20 kg	600 mg (12 mL)	About US$490,000
30 kg	900 mg (18 mL)	About US$730,000
40 kg	1,200 mg (24 mL)	About US$980,000

These are our own estimates from US list prices and are not a quotation. In Pakistani rupees, this is well over PKR 100 million per year for even a smaller child. The cost rises as the child grows. Prices from intermediaries and online brokers can be several times higher than the US list price, so never rely on an unofficial website.

Where Is It Available?

• United States: Approved by the FDA, and sold only as a brand-name product with no generic version.
• Europe: Not approved by the European Medicines Agency. In some countries, doctors can prescribe it through a managed (named-patient) access programme, where funding can be secured.
• Middle East and elsewhere: The manufacturer has said that it supplies the medicine through distributors on a named-patient basis in places such as Israel, Brazil and certain Middle Eastern countries. Some sources list approvals in the UAE and Saudi Arabia, and families should confirm this with the regulator or the hospital.
• Pakistan: To our knowledge, eteplirsen is not registered with the Drug Regulatory Authority of Pakistan (DRAP) and is not stocked in Pakistan. Some Indian intermediaries advertise that they can supply it to SAARC countries including Pakistan. Please be very cautious and use official channels only.

Can It Be Brought to Pakistan?

In principle, yes, but only through a legal route. DRAP has said that an unregistered or unavailable medicine can be imported by a hospital or health institution with DRAP permission under its rules for the import of unregistered drugs for hospital and institutional use (S.R.O. 134(I)/2021, with an updated exemption notified in August 2025). In practice, this means:

1. A treating specialist at a registered hospital confirms the diagnosis and that the child's gene change is amenable to exon 51 skipping.
2. The hospital applies to DRAP for permission to import the medicine for a named patient.
3. The medicine is obtained from the manufacturer or an authorised distributor, with cold-chain handling and proper documentation.
4. Someone has to fund it, and the infusions have to be given every week by a trained team, with monitoring for reactions and kidney function.

DRAP has also warned hospitals to import only through proper channels after problems with unregistered medicines, and has begun to require 2D barcodes on registered medicines from October 9, 2026, to fight fake medicines. Families should never buy this medicine from social media sellers, WhatsApp groups or unofficial websites. A fake or badly stored infusion can be dangerous.

How Could the Cost Be Reduced?

There is no secret trick, but there are legitimate steps that can reduce the cost or avoid wasted money:

1. Confirm eligibility first. Only about one in seven boys with Duchenne can benefit, so do not spend a rupee before the genetic report shows an exon 51-amenable change.
2. Ask the manufacturer for a quotation and access options. Companies run named-patient and patient support programmes. Terms differ by country, and they are decided case by case.
3. Use an official route, not brokers. Import through a hospital and an authorised distributor avoids the extra mark-ups of intermediaries.
4. Look for clinical trials. Trials supply the medicine free of charge to those who qualify, but they enrol only a few places and strict criteria apply.
5. Negotiate as a group. A government or a consortium that buys for several patients can seek a lower price, a volume discount or payment linked to results, instead of each family bargaining alone.
6. Seek independent funding. Charitable funds, philanthropic donors and international rare disease networks sometimes support access for a limited number of patients, though not for the long run, because the infusions never stop.
7. Keep proven care funded first. Steroids, heart checks, breathing care and vaccinations cost a small fraction and have a much stronger evidence base. They should never be dropped to pay for an expensive medicine.

What Can the Government Do?

Eteplirsen is a policy challenge, not just a family problem. Governments in other countries use several tools, and Pakistan could consider them:

• A rare disease policy and an orphan drug pathway. DRAP's board approved a draft orphan drug policy several years ago, with faster registration and a separate pricing approach for rare disease medicines. Finalising and putting it into practice would give families a clear pathway.
• A national registry of Duchenne patients. A registry shows how many boys have exon 51-amenable changes, so that policy is based on real numbers. MDP's patient registration portal is a first step.
• Genetic testing support. Funded genetic testing lets families know whether they are even eligible, and supports counselling.
• Managed-entry agreements. A government can negotiate a price-volume deal or a payment that is only continued if the child shows benefit. This is very relevant for a medicine whose benefit is still being confirmed.
• Independent evidence review (health technology assessment). A formal review of the clinical evidence and the price, after the confirmatory trial results are available, would help decide whether and how to fund it.
• Funding the basics. Making steroids, heart and breathing care, home ventilation and genetic counselling reliably available helps every boy with Duchenne, not only the few who are amenable to one exon.
• Using existing funding channels. Provincial health programmes, Bait-ul-Mal and other social protection programmes could be asked whether a rare disease window can be created. Coverage differs by province, and, to our knowledge, there is no dedicated national programme that pays for Duchenne medicines at present.

Governments have to balance the needs of many patients with limited budgets, and the evidence for this medicine is still developing. That is why patient organisations ask for a clear process, transparent evidence review, and fair pricing, rather than for a blank cheque.

What Families Can Do Now

1. Ask for a complete genetic report that shows the exact change in the DMD gene.
2. Ask your neurologist whether your child's change is amenable to exon 51 skipping and what the current evidence means for your child.
3. Make sure the proven care is in place: steroids as advised, regular heart checks, breathing care and vaccines. Our Duchenne guide explains each of these in detail.
4. Do not pay any broker or online seller. If someone offers the medicine, check with the specialist and DRAP first.
5. Register with MDP, so that the number of boys who could be affected by access decisions is known and heard.

Frequently Asked Questions

Is eteplirsen a cure for Duchenne?

No. It aims to produce a small amount of a shorter dystrophin protein. It is not a cure, and its clinical benefit is still being confirmed.

Can any boy with Duchenne use it?

No. It is only for boys with a gene change amenable to exon 51 skipping, around 13% to 14% of people with Duchenne.

Is it available in Pakistan?

To our knowledge, it is not registered or stocked in Pakistan. A hospital can apply to DRAP for permission to import an unregistered medicine for a named patient, but funding and weekly infusions remain big challenges.

Is there a cheaper generic version?

No generic version is currently available.

Are other exon-skipping medicines available?

Other exon-skipping medicines exist for other exons (such as exon 53 and exon 45), and each only suits a small group of patients, with similar cost and evidence questions. Your specialist can advise on which, if any, matches your child's gene change.

Does stopping steroids make sense if we start eteplirsen?

No. Steroids remain the standard treatment, and trials of eteplirsen have enrolled boys on stable steroid treatment. Do not change medicines without your doctor's advice.

Muscular Dystrophy Pakistan Every patient counts. Register with MDP. Patients and families living with muscular dystrophy and other neuromuscular disorders can register on the MDP patient registration portal. Your registration helps us understand the real picture and speak up for timely diagnosis, care and support. ✔ Simple online registration ✔ For patients and families ✔ Helps make every patient visible Register Now → musculardystrophypk.org/registration

Hope Needs Honesty and a Plan

Families deserve both hope and the truth. The truth is that eteplirsen helps only a minority of boys, its benefit is still being confirmed, and its price is out of reach for almost every family in Pakistan. Hope lies in building a system: counted patients, genetic testing, funded basic care, a fair process for evaluating new medicines, and a government that talks to patients. Follow the MDP blog for more research and access updates.

Sources and Further Reading

• Sarepta Therapeutics, Announcement of FDA accelerated approval of EXONDYS 51 (eteplirsen)
• Institute for Clinical and Economic Review (ICER), Final report and policy recommendations on treatments for Duchenne muscular dystrophy (2019)
• BioPharma Dive, Sarepta names that price
• Drugs.com, Exondys 51 price guide
• BioSpace, European regulators reject Exondys 51
• Muscular Dystrophy News, Exondys 51 managed access programme
• Business Recorder, DRAP for importing only registered/enlisted drugs
• Drug Regulatory Authority of Pakistan, SROs and notifications
• The Express Tribune, DRAP working on orphan drug policy

Medical and financial disclaimer: This article is for awareness and education only. It is not medical, legal or financial advice. Prices are estimates from published list prices and may change. Please discuss any treatment decision with your child's specialist, and do not buy prescription medicines from unofficial sellers.